Helus Pharma Inc. Stock 12‑Month Price Target Raised to $43.62, Implies 299% Upside

Helus Pharma Inc.'s average stock price target increased from $40.77 to $43.62, according to 9 analysts, with a potential 299% upside from the Oct. 20 closing price. The consensus rating remains 'Buy' among 10 analysts.

Original reporting
Published Oct 21, 2026, 4:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 4:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Helus Pharma Inc. Stock 12‑Month Price Target Raised to $43.62, Implies 299% Upside — source image
Decision brief

The 30-second read

Low
01

Why it matters

The target raise signals improved expectations but lacks a concrete catalyst.

02

Market read

Modest relevance; may affect short‑term sentiment for the stock and similar small‑cap biotech names.

03

What to watch

Potential dilution from upcoming financing or clinical trial risk.

Relevance 5/10Novelty 5/10Timing: today

Background

Helus Pharma is a micro‑cap biotech with recent analyst coverage.

Market effects

May lift sentiment for small-cap biotech peers.

Limited to US biotech market.

Minimal.

Counterpoint

Target could be overly optimistic; price may remain flat.

Key entities

  • Helus Pharma Inc.

    US‑listed biotech (NASDAQ:HLPH).

Related articles

$HELPMed

HELP Stock Slides As Suicide Attempt Overshadows Strong Late-stage Depression Trial Data

HELP stock declined despite positive late-stage trial data for its depression drug, HLP003. The drug showed significant improvements in patients, with 56% seeing at least a 50% improvement at six weeks. Analysts like Lucid Capital raised their price target to $79, citing strong results, while Jefferies and Barclays maintained 'Buy' and 'Overweight' ratings, respectively. Retail sentiment on Stocktwits turned 'extremely bullish'.

$HELPMedAI 8/10

Helus Pharma falls 10.5% despite positive HLP003 trial

Helus Pharma (HELP) reported positive results for its experimental drug HLP003, meeting the primary endpoint in a late-stage depression trial. Despite this, shares fell 10.5% to $7.94, with three serious adverse events disclosed. Analysts noted strong efficacy and no fundamental reason for the decline. The company is also developing HLP004 for anxiety and expects to identify an HLP005 candidate in late 2027.

MedAI 8/10

Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depression

Helus Pharma reported that its deuterated psilocin therapy, HLP003, significantly reduced major depressive disorder symptoms in a late-stage trial, but its stock fell due to three undisclosed serious adverse events. The trial met primary and secondary endpoints, with a 19.5-point reduction in symptoms versus 11.9 for placebo. Analysts noted the efficacy but emphasized the need for safety clarification. The company expects further trial results in 2027.

HighAI 8/10

Helus Pharma's psychedelic depression drug succeeds in late-stage study, shares jump

Helus Pharma reported that its psychedelic drug, HLP003, showed significant improvement in depression symptoms in a late-stage trial. The drug, a modified version of psilocin, is designed to be used with standard antidepressants. The company's shares rose over 20% in premarket trading. According to Helus, 56.3% of patients treated with HLP003 saw their symptoms cut by at least half, compared with 28.2% on placebo.